Results 11 to 20 of about 9,615 (165)

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

open access: yesCell Death Discovery, 2022
Altered features of tumor cells acquired across therapy can result in the survival of treatment-resistant clones that may cause minimal residual disease (MRD).
Viktoria Fuhr   +7 more
doaj   +2 more sources

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

open access: yesPharmaceutics, 2022
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu   +6 more
doaj   +2 more sources

A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia

open access: yesCase Reports in Oncological Medicine, 2016
Introduction. Ibrutinib is commonly used for the treatment of patients with CLL in either first-line or relapsed/refractory settings. Case Presentation.
William Paul Skelton IV   +10 more
doaj   +2 more sources

Enhanced Cardiomyocyte Reactive Oxygen Species Signaling Promotes Ibrutinib-Induced Atrial Fibrillation

open access: yesRedox Biology, 2020
Atrial fibrillation (AF) occurs in up to 11% of cancer patients treated with ibrutinib. The pathophysiology of ibrutinib promoted AF is complicated, as there are multiple interactions involved; the detailed molecular mechanisms underlying this are still ...
Xinye Li, Yanwei Xing, Nian Liu
exaly   +3 more sources

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study [PDF]

open access: yesJournal of Hematology & Oncology, 2022
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are ...
Narendranath Epperla   +44 more
doaj   +2 more sources

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae

open access: yesFrontiers in Pharmacology, 2021
Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
doaj   +1 more source

Ibrutinib-related uveitis: A case series

open access: yesAmerican Journal of Ophthalmology Case Reports, 2022
Purpose: Four cases of ibrutinib-related uveitis are presented, which are to the best of our knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are explored.
Zelia K. Chiu   +4 more
doaj   +1 more source

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

open access: yesHaematologica, 2021
Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment.
Joshua N. Gustine   +18 more
doaj   +1 more source

Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS

open access: yesMolecules, 2023
Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib,
Lu-Ning Sun   +7 more
doaj   +1 more source

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. [PDF]

open access: yes, 2014
BACKGROUND: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome.
Thornton, P   +36 more
core   +3 more sources

Home - About - Disclaimer - Privacy